Asarfi Hospital

  • Market Cap: Micro Cap
  • Industry: Hospital
  • ISIN: INE0DN001027
  • NSEID:
  • BSEID: 543943
INR
197.90
0.00 (0.00%)
BSENSE

Dec 04

BSE+NSE Vol: 21000

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

21.0 k (-20.45%) Volume

Shareholding (Sep 2025)

FII

0.05%

Held by 1 FIIs

DII

2.19%

Held by 0 DIIs

Promoter

61.17%

What does Asarfi Hospital do?

06-Jun-2025

Asarfi Hospital Ltd is a micro-cap company in the hospital industry, incorporated in 2005 and converted to a public limited company in 2012. As of March 2025, it reported net sales of 34 Cr and a net profit of 4 Cr, with a market cap of Rs 268 Cr.

Overview: <BR>Asarfi Hospital Ltd operates in the hospital industry and is categorized as a micro-cap company.<BR><BR>History: <BR>Asarfi Hospital Limited was originally incorporated as a Private Limited Company on October 4, 2005, under the name "Asarfi Hospital Private Limited." The company later converted its status to Public Limited and changed its name to "Asarfi Hospital Limited" on February 08, 2012. The most recent quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 34 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 4 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 268 Cr (Micro Cap) <BR><BR>Key Metrics: <BR>P/E: 24.00 <BR>Industry P/E: 54 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.20 <BR>Return on Equity: 15.58% <BR>Price to Book: 3.76 <BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Read More

Has Asarfi Hospital declared dividend?

06-Jun-2025

No Dividend History Available

What is the technical trend for Asarfi Hospital?

09-Jun-2025

As of May 19, 2025, Asarfi Hospital's technical trend is bullish, supported by a positive MACD and moving averages, although the weekly RSI indicates some potential weakness in momentum.

As of 19 May 2025, the technical trend for Asarfi Hospital has changed from mildly bullish to bullish. The weekly MACD is bullish, supporting the positive trend, while the daily moving averages also indicate bullish momentum. The Bollinger Bands are bullish on both weekly and monthly time frames, reinforcing the strength of the current trend. However, the weekly RSI is bearish, suggesting some potential weakness in momentum. Dow Theory indicates a mildly bullish stance on both weekly and monthly time frames. Overall, the current technical stance is bullish with moderate strength, driven primarily by the bullish MACD and moving averages.

Read More

Who are the peers of the Asarfi Hospital?

16-Jul-2025

Asarfi Hospital's peers include GPT Healthcare, KMC Speciality, Aashka Hospitals, and others, with varying management risks and growth rates. Asarfi Hospital has a good management risk and a 1-year return of 92.36%, outperforming its peers.

Peers: The peers of Asarfi Hospital are GPT Healthcare, KMC Speciality, Abate As Indust, Aashka Hospitals, Aprameya Enginee, Unihealth Hosp, Chandan Healthca, Nephro Care, KHFM Hospitality, and Maitreya Medica.<BR><BR>Quality Snapshot: Excellent management risk is observed at GPT Healthcare and Chandan Healthca, while Average management risk is found at KMC Speciality and KHFM Hospitality. Good management risk is noted at Asarfi Hospital, Aprameya Enginee, Unihealth Hosp, and Nephro Care, while Below Average management risk is present at Aashka Hospitals. Growth is Excellent at Aprameya Enginee and Nephro Care, Below Average at GPT Healthcare, KMC Speciality, Asarfi Hospital, Aashka Hospitals, and KHFM Hospitality, and does not qualify for Abate As Indust. Capital Structure is Excellent at GPT Healthcare and KMC Speciality, Good at Asarfi Hospital, Nephro Care, and Chandan Healthca, Below Average at Aprameya Enginee, Unihealth Hosp, Aashka Hospitals, and KHFM Hospitality, and does not qualify for Abate As Indust.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Abate As Indust at 46.07%, while the lowest is KMC Speciality at -19.73%. Asarfi Hospital's 1-year return is 92.36%, which is significantly higher than both. Additionally, KMC Speciality, Aashka Hospitals, and KHFM Hospitality have negative six-month returns.

Read More

Who are in the management team of Asarfi Hospital?

16-Jul-2025

As of March 2023, the management team of Asarfi Hospital includes Udai Pratap Singh (Managing Director), Madhuri Singh (Executive Director), Sukanti Kumar Das (Director), Amit Kumar Barnwal (Independent Director), Rajkumari Sharma (Independent Director), and Seepika Gupta (Company Secretary & Compliance Officer). Each member contributes to the hospital's governance and operations.

As of March 2023, the management team of Asarfi Hospital includes the following individuals:<BR><BR>1. Udai Pratap Singh - Managing Director<BR>2. Madhuri Singh - Executive Director<BR>3. Sukanti Kumar Das - Director<BR>4. Amit Kumar Barnwal - Independent Director<BR>5. Rajkumari Sharma - Independent Director<BR>6. Seepika Gupta - Company Secretary & Compliance Officer<BR><BR>Each member plays a crucial role in the governance and operational oversight of the hospital.

Read More

Who are the top shareholders of the Asarfi Hospital?

17-Jul-2025

The top shareholders of Asarfi Hospital include Harendra Singh with 18.78%, followed by public shareholder Gopal Singh at 2.4%. Individual investors collectively own 30.86% of the shares, with no pledged promoter holdings or involvement from mutual funds or foreign institutional investors.

The top shareholders of Asarfi Hospital primarily consist of the promoters, with Harendra Singh holding the largest stake at 18.78%. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors involved. The highest public shareholder is Gopal Singh, who holds 2.4%. Additionally, individual investors collectively own 30.86% of the shares.

Read More

How big is Asarfi Hospital?

24-Jul-2025

As of 24th July, Asarfi Hospital Ltd has a market capitalization of 261.00 Cr, with net sales of 110.87 Cr and a net profit of 6.01 Cr over the last four quarters. Shareholder's funds are 70.41 Cr, and total assets amount to 154.09 Cr as of March 2024.

As of 24th July, <BR><BR>Market Cap: Asarfi Hospital Ltd has a market capitalization of 261.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 110.87 Cr, while the sum of Net Profit for the same period is 6.01 Cr.<BR><BR>Balance Sheet Snapshot: The latest reporting period is March 2024. Shareholder's Funds stand at 70.41 Cr, and Total Assets amount to 154.09 Cr.

Read More

When is the next results date for Asarfi Hospital?

01-Aug-2025

Asarfi Hospital will declare its results on 07 August 2025.

Asarfi Hospital will declare its results on 07 August 2025.

Read More

Are Asarfi Hospital latest results good or bad?

12-Nov-2025

Asarfi Hospital's Q2 FY26 results are strong, with a net profit of ₹4.20 crores, a 47.37% year-on-year increase, and revenue growth of 45.46% to ₹44.89 crores, marking the highest quarterly revenue in its history. The operating margin is 19.76%, indicating solid profitability and effective capital management.

Asarfi Hospital's latest results for Q2 FY26 are quite strong, indicating a positive performance. The company reported a net profit of ₹4.20 crores, which reflects a significant increase of 47.37% year-on-year and a 34.62% sequential growth from the previous quarter. Additionally, revenue grew by 45.46% year-on-year, reaching ₹44.89 crores, marking the highest quarterly revenue in the company's history.<BR><BR>The operating margin stands at a healthy 19.76%, showcasing the company's ability to maintain profitability while scaling operations. Furthermore, the return on equity is a commendable 15.99%, indicating effective capital management.<BR><BR>Overall, the results highlight Asarfi Hospital's robust growth trajectory and operational efficiency, positioning it well within the healthcare sector.

Read More

How has been the historical performance of Asarfi Hospital?

15-Nov-2025

Asarfi Hospital experienced significant growth in net sales and profits from Mar'24 to Mar'25, with net sales rising to 120.57 Cr and profit after tax increasing to 10.58 Cr. However, cash flow from operating activities turned negative, indicating challenges in cash management despite strong revenue performance.

Answer:<BR>The historical performance of Asarfi Hospital shows significant growth from the previous year, with net sales increasing from 84.40 Cr in Mar'24 to 120.57 Cr in Mar'25. Total operating income mirrored this growth, rising to 120.57 Cr from 84.40 Cr. The total expenditure also increased, from 68.35 Cr to 97.01 Cr, primarily driven by higher raw material costs and other expenses. Operating profit (PBDIT) rose to 31.08 Cr from 17.72 Cr, while profit before tax improved from 6.24 Cr to 14.31 Cr. Consequently, profit after tax saw a substantial increase from 4.16 Cr to 10.58 Cr, resulting in an earnings per share (EPS) growth from 2.11 to 5.38. <BR><BR>In terms of balance sheet performance, shareholder's funds increased to 80.98 Cr from 70.41 Cr, and total liabilities rose to 163.89 Cr from 154.09 Cr. Long-term borrowings also increased significantly from 17.45 Cr to 33.83 Cr. Current assets improved to 58.48 Cr from 45.60 Cr, with notable increases in sundry debtors and inventories. However, cash flow from operating activities turned negative, dropping from 26.00 Cr to -4.00 Cr, while cash flow from financing activities decreased from 36.00 Cr to 12.00 Cr. Overall, Asarfi Hospital demonstrated strong revenue and profit growth, despite challenges in cash flow management.

Read More

Should I buy, sell or hold Asarfi Hospital?

16-Nov-2025

Is Asarfi Hospital overvalued or undervalued?

17-Nov-2025

As of November 14, 2025, Asarfi Hospital is considered overvalued with a PE ratio of 31.38 and an EV to EBITDA of 16.34, despite strong stock performance, indicating it may not be an attractive investment compared to peers like Apollo Hospitals and Max Healthcare.

As of 14 November 2025, Asarfi Hospital's valuation grade has moved from very attractive to attractive, indicating a shift in market perception. The company is currently assessed as overvalued. Key ratios include a PE ratio of 31.38, an EV to EBITDA of 16.34, and a PEG ratio of 0.20, which suggests growth potential relative to its valuation. <BR><BR>In comparison to peers, Apollo Hospitals has a significantly higher PE ratio of 63.77 and an EV to EBITDA of 33.53, while Max Healthcare is marked as very expensive with a PE of 89.07. Despite the recent strong stock performance, with a year-to-date return of 75.1% compared to the Sensex's 8.22%, the elevated valuation metrics indicate that Asarfi Hospital may not present an attractive investment opportunity at current levels.

Read More

Why is Asarfi Hospital falling/rising?

05-Dec-2025

As of 04-Dec, Asarfi Hospital Ltd's stock price is at Rs 197.90, reflecting a recovery from an earlier loss and a strong monthly increase of 37.96%. The stock has surged 97.90% year-to-date and 120.01% over the past year, driven by strong financial results and increased investor participation.

As of 04-Dec, Asarfi Hospital Ltd's stock price is rising, currently at Rs 197.90, reflecting a change of 1.05 (0.53%) upward. This increase comes despite the stock opening with a loss of -4.29% earlier in the day, indicating a recovery from its intraday low of Rs 188.4. The stock also reached an intraday high of Rs 202, showcasing some volatility but ultimately closing higher.<BR><BR>The stock's performance over the past month has been particularly strong, with a remarkable increase of 37.96%, significantly outperforming the Sensex, which only rose by 2.16% during the same period. Year-to-date, the stock has surged by 97.90%, and over the past year, it has generated an impressive return of 120.01%, far exceeding the market's average return of 5.32%. <BR><BR>Additionally, the company has reported strong financial results, including a 34.38% growth in net profit and record high net sales of Rs 44.89 crore, which have positively influenced investor sentiment. The rising investor participation, evidenced by a 54.87% increase in delivery volume compared to the 5-day average, further supports the stock's upward movement. <BR><BR>While there are some concerns regarding management efficiency and institutional investor participation, the overall positive financial performance and market-beating returns appear to be driving the stock's rise.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Strong ability to service debt as the company has a low Debt to EBITDA ratio of 1.44 times

 
2

With a growth in Net Profit of 34.38%, the company declared Very Positive results in Sep 25

3

With ROCE of 8.6, it has a Attractive valuation with a 3.3 Enterprise value to Capital Employed

4

Market Beating Performance

stock-summaryMojo Parameters
Mojo Parameters
Loading Valuation Snapshot...
Stock DNA
stock-summary
Industry

Hospital

stock-summary
Market cap

INR 390 Cr (Micro Cap)

stock-summary
P/E

35.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.53

stock-summary
Return on Equity

12.97%

stock-summary
Price to Book

4.67

Revenue and Profits:
Net Sales:
45 Cr
(Quarterly Results - Sep 2025)
Net Profit:
4 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (0%)
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
59.6%
0%
59.6%
6 Months
46.81%
0%
46.81%
1 Year
114.06%
0%
114.06%
2 Years
102.1%
0%
102.1%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

Asarfi Hospital for the last several years.

Risk Adjusted Returns v/s stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryNews & Corporate Actions
Announcements stock-summary

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

02-Dec-2025 | Source : BSE

This is to inform you that the Company will be meeting Investors/Analysts on dated November 04 2025 organized by Hem Securities - Samrudhi 2025 Virtual SME Conclave.

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

27-Nov-2025 | Source : BSE

We wish to inform you that the management of the Company will be participating in Samruddhi2025(Season 2) - Nav Bharat ka Caravan Virtual Investor-Company Connect Conference organized by Hem Securities Limited which brings together some of Indias most emerging fast-growing and high-potential companies.

Announcement under Regulation 30 (LODR)-Earnings Call Transcript

22-Nov-2025 | Source : BSE

We hereby submit the transcript of the Earning Conference call held on November 19 2025 wherein the Unaudited Standalone & Consolidated financial Results for the half year ended September 30 2025 (FY26).

Corporate Actions stock-summary
stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

No Dividend history available

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available

stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
22.70%
EBIT Growth (5y)
14.76%
EBIT to Interest (avg)
5.07
Debt to EBITDA (avg)
2.00
Net Debt to Equity (avg)
0.53
Sales to Capital Employed (avg)
0.92
Tax Ratio
25.36%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
2.24%
ROCE (avg)
8.69%
ROE (avg)
9.73%
Valuation key factors
Factor
Value
P/E Ratio
35
Industry P/E
0
Price to Book Value
4.60
EV to EBIT
38.71
EV to EBITDA
18.22
EV to Capital Employed
3.35
EV to Sales
3.61
PEG Ratio
0.22
Dividend Yield
NA
ROCE (Latest)
8.65%
ROE (Latest)
12.97%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Dow Theory
Bullish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Sep 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 0 Schemes

FIIs

Held by 1 FIIs (0.05%)

Promoter with highest holding

Harendra Singh (18.78%)

Highest Public shareholder

Gopal Singh (2.4%)

Individual Investors Holdings

30.89%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Sep'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is 25.77% vs 5.22% in Jun 2025",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is 34.37% vs -16.45% in Jun 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Jun'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "44.85",
          "val2": "35.66",
          "chgp": "25.77%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "8.91",
          "val2": "7.03",
          "chgp": "26.74%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.07",
          "val2": "1.22",
          "chgp": "-12.30%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "4.30",
          "val2": "3.20",
          "chgp": "34.37%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "19.87%",
          "val2": "19.71%",
          "chgp": "0.16%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Standalone) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Mar 2025 is 24.17% vs 22.01% in Sep 2024",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": " Growth in half year ended Mar 2025 is 47.86% vs 107.01% in Sep 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "66.78",
          "val2": "53.78",
          "chgp": "24.17%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "12.22",
          "val2": "11.62",
          "chgp": "5.16%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "2.52",
          "val2": "1.56",
          "chgp": "61.54%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "6.55",
          "val2": "4.43",
          "chgp": "47.86%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "18.30%",
          "val2": "21.61%",
          "chgp": "-3.31%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Standalone) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in nine months ended Dec 2024 is 1.76% vs 6.00% in Sep 2025",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in nine months ended Dec 2024 is 12.24% vs -33.58% in Sep 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "86.67",
          "val2": "85.17",
          "chgp": "1.76%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "18.60",
          "val2": "17.01",
          "chgp": "9.35%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "2.74",
          "val2": "2.40",
          "chgp": "14.17%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "7.15",
          "val2": "6.37",
          "chgp": "12.24%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "21.46%",
          "val2": "19.97%",
          "chgp": "1.49%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Standalone) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is 42.86% vs 19.38% in Mar 2024",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is 160.81% vs -47.51% in Mar 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "120.57",
          "val2": "84.40",
          "chgp": "42.86%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "23.85",
          "val2": "16.09",
          "chgp": "48.23%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "4.08",
          "val2": "2.69",
          "chgp": "51.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "10.98",
          "val2": "4.21",
          "chgp": "160.81%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "19.78%",
          "val2": "19.06%",
          "chgp": "0.72%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Standalone) - Sep'25 - QoQstock-summary
Sep'25
Jun'25
Change(%)
Net Sales
44.85
35.66
25.77%
Operating Profit (PBDIT) excl Other Income
8.91
7.03
26.74%
Interest
1.07
1.22
-12.30%
Exceptional Items
0.00
0.00
Standalone Net Profit
4.30
3.20
34.37%
Operating Profit Margin (Excl OI)
19.87%
19.71%
0.16%
Values in Rs Cr.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Sep 2025 is 25.77% vs 5.22% in Jun 2025

Direction Arrows
Standalone Net Profit

QoQ Growth in quarter ended Sep 2025 is 34.37% vs -16.45% in Jun 2025

Half Yearly Results Snapshot (Standalone) - Mar'25stock-summary
Mar'25
Sep'24
Change(%)
Net Sales
66.78
53.78
24.17%
Operating Profit (PBDIT) excl Other Income
12.22
11.62
5.16%
Interest
2.52
1.56
61.54%
Exceptional Items
0.00
0.00
Standalone Net Profit
6.55
4.43
47.86%
Operating Profit Margin (Excl OI)
18.30%
21.61%
-3.31%
Values in Rs Cr.
Direction Arrows
Net Sales

Growth in half year ended Mar 2025 is 24.17% vs 22.01% in Sep 2024

Direction Arrows
Standalone Net Profit

Growth in half year ended Mar 2025 is 47.86% vs 107.01% in Sep 2024

Nine Monthly Results Snapshot (Standalone) - Dec'24stock-summary
Dec'24
Sep'25
Change(%)
Net Sales
86.67
85.17
1.76%
Operating Profit (PBDIT) excl Other Income
18.60
17.01
9.35%
Interest
2.74
2.40
14.17%
Exceptional Items
0.00
0.00
Standalone Net Profit
7.15
6.37
12.24%
Operating Profit Margin (Excl OI)
21.46%
19.97%
1.49%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in nine months ended Dec 2024 is 1.76% vs 6.00% in Sep 2025

Direction Arrows
Standalone Net Profit

YoY Growth in nine months ended Dec 2024 is 12.24% vs -33.58% in Sep 2025

Annual Results Snapshot (Standalone) - Mar'25stock-summary
Mar'25
Mar'24
Change(%)
Net Sales
120.57
84.40
42.86%
Operating Profit (PBDIT) excl Other Income
23.85
16.09
48.23%
Interest
4.08
2.69
51.67%
Exceptional Items
0.00
0.00
Standalone Net Profit
10.98
4.21
160.81%
Operating Profit Margin (Excl OI)
19.78%
19.06%
0.72%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2025 is 42.86% vs 19.38% in Mar 2024

Direction Arrows
Standalone Net Profit

YoY Growth in year ended Mar 2025 is 160.81% vs -47.51% in Mar 2024

stock-summaryCompany CV
About Asarfi Hospital Ltd stock-summary
stock-summary
Asarfi Hospital Ltd
Micro Cap
Hospital
Asarfi Hospital Limited was originally incorporated as Private Limited Company in the name of "Asarfi Hospital Private Limited" on October 4, 2005 issued by Registrar of Companies, Bihar & Jharkhand. Subsequently, status of the Company was converted into Public Limited and name of the Company was changed to "Asarfi Hospital Limited" vide a fresh Certificate of Incorporation dated February 08, 2012 issued by Registrar of Companies, Jharkhand.
Company Coordinates stock-summary
Icon
No Company Details Available